Chronic Myelod Leukemia Registry at Asan Medical Center

Prospective Observational Cohort Registry for Patients With Chronic Myeloid Leukemia at Asan Medical Center

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01761695

Enrollment

100

Registered

2013-01-07

Start date

2013-01-31

Completion date

2016-05-31

Last updated

2018-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leukemia, Chronic Myeloid, Myeloid Leukemia, Chronic, Accelerated Phase, Myeloid Leukemia, Chronic, Chronic Phase

Brief summary

The investigators would like to propose a prospective longitudinal observational cohort study for patients who will be diagnosed and/or treated for chronic myeloid leukemia at Asan Medical Center, Seoul, Korea, to use the acquired data for fundamentals of other retrospective analysis.

Detailed description

1. Acquisition of informed concent form 2. Data acquisition from medical record including * demographic / disease-associated factors * details of treatment, and its results * complications during treatment * genetic data * survival outcome (upto 30 years) 3. Accumulation of data for 30 years 4. Use of data for other retrospective analysis (including Asan Medical center Cell Banking basic data)

Interventions

OTHERDiagnosed as CML

All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as chronic myeloid leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

15 Years to No maximum

Healthy volunteers

Inclusion criteria

* All patients who are diagnosed and/or treated as chronic myeloid leukemia at Asan Medical Center * 15 years of age and over * All patients who give written consent according to guidelines at Asan Medical Center committee on human research

Exclusion criteria

* Patients who refuse to give consent to registering

Design outcomes

Primary

Measure	Time frame
Overall survival	30 years

Secondary

Measure	Time frame	Description
Event-free survival	30 years	Definition of events will be as 'failure', 'progress to AP/BC', 'intolerant and medication change', and 'death from any cause'.
Failure-free survival	30 years	Failure will be defined as BCR-ABL elevation at 2 serial times, progression to AP/BC, loss of hematologic / cytogenetic response, any appearance of ABL kinase mutation, and clonal evolution.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026